Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S342000, C514S236800, C514S255050, C544S133000, C544S405000, C546S270400, C546S269700, C546S209000, C548S202000
Reexamination Certificate
active
07135488
ABSTRACT:
The present invention relates to compounds of formula (I)wherein R1, R2, R3, R4, R5, R6and R7are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
REFERENCES:
patent: 3940418 (1976-02-01), Hamilton
patent: 5342851 (1994-08-01), Sanfilippo et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 2004/0167129 (2004-08-01), Mayweg et al.
patent: 576357 (1993-12-01), None
patent: 656354 (1995-06-01), None
patent: 658546 (1995-06-01), None
patent: WO9602248 (1996-02-01), None
patent: WO9719063 (1997-05-01), None
patent: WO0015609 (2000-03-01), None
patent: WO 00 46209 (2000-08-01), None
patent: WO0046209 (2000-08-01), None
patent: WO0132663 (2001-05-01), None
patent: WO 01 58869 (2001-08-01), None
patent: WO0164632 (2001-09-01), None
patent: WO0164633 (2001-09-01), None
patent: WO0164634 (2001-09-01), None
patent: WO0170700 (2001-09-01), None
patent: WO0228346 (2002-04-01), None
Pacheco, M., et al., Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors, Journal of Pharmacology and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1).
Casiano, F.M., et al., Putative Aminoalkylindoles (AAI) Antagonists, Problems of Drug Dependence 1990: Proceedings of the 52ndAnnual Scientific Meeting The Committeee on Problems of Drug Dependence, 1991, pp. 295-296, v. 105.
Hosohata, K., et al., AM630 is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life Sciences, 1997, pp. 115-118, v. 61(9).
Pertwee, R., et al., AM630, A Competitive Cannabinoid Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v. 56(23/24).
Felder, C.C., et al., LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation, Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 291-297, v. 284(1).
Kanyonyo, M. et al., 3-Alkyl-(5,5'-Diphenyl) Imidazolidinediones As New Cannabinoid Ligands, Bioorganic & Medicinal Chemistry Letters, 1999, pp. 2233-2236, v. 9.
Ooms, F., et al., Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB1Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling, J. Med. Chem., 2002, pp. 1748-1756, v. 45(9).
Guba Wolgang
Haap Wolfgang
Marty Hans Peter
Narquizian Robert
Hoffmann-La Roche Inc.
Johnston George W.
Remy Brian C.
Rocha-Tramaloni Patricia S.
Stockton Laura L.
LandOfFree
Pyrrolyl-thiazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolyl-thiazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolyl-thiazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668677